Biognosys, Alamar Biosciences Join Forces To Advance Proteomics Research

KUALA LUMPUR, April 5 (Bernama) -- Biognosys, a global leader in mass spectrometry-based proteomics and Alamar Biosciences Inc, a company powering precision proteomics, has entered into a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomics biomarkers.

This collaboration brings together Biognosys' expertise in unbiased discovery through data independent acquisition mass spectrometry (DIA-MS) and Alamar's cutting-edge immunoassays, according to a statement.

This integrated approach enhances Biognosys’ understanding of biomarkers by combining deep unbiased DIA-MS discovery proteomics with highly specific and ultra-sensitive mid- and high-plex NULISA assays for low-abundance proteins such as cytokines, chemokines and important disease protein biomarkers from plasma.

"Our combined efforts will pave the way for breakthroughs in plasma biology by analysing in an unbiased way more than 5,000 proteins together with panels of hundreds of well characterised cytokines and other high value low abundance proteins using highly specific NULISA assays," said Biognosys Founder and Chief Executive Officer (CEO), Oliver Rinner.

Meanwhile, Alamar Chairman, Founder and CEO, Yuling Luo said: "We are thrilled to partner with Biognosys to provide the research community with expanded access to proteomic insights from discovery through to clinical research."

This partnership underscores the commitment of both companies to scientific excellence and their shared vision of advancing precision medicine through innovative technologies.

In the Industry Spotlight Theater session hosted by Alamar at the American Society for Cancer Research 2024 Annual Meeting in San Diego on April 9, the companies will jointly present data from a collaborative study focused on Non-Small Cell Lung Cancer.

The findings demonstrate the feasibility of integrated analysis and highlight the complementary insights derived from mass spectrometry and affinity-based assays in plasma.

Building upon this successful proof-of-concept study, Biognosys and Alamar are planning to further collaborate both commercially and scientifically as part of their strategic partnership.

-- BERNAMA